Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Reduced by Rhumbline Advisers

Rhumbline Advisers cut its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 1.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,531 shares of the biotechnology company’s stock after selling 1,318 shares during the period. Rhumbline Advisers owned 0.14% of Blueprint Medicines worth $7,547,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Asset Management One Co. Ltd. acquired a new position in Blueprint Medicines in the fourth quarter worth approximately $88,000. Van ECK Associates Corp grew its position in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares in the last quarter. Values First Advisors Inc. increased its stake in shares of Blueprint Medicines by 277.9% during the 4th quarter. Values First Advisors Inc. now owns 4,970 shares of the biotechnology company’s stock worth $433,000 after purchasing an additional 3,655 shares during the last quarter. Stephens Inc. AR bought a new position in shares of Blueprint Medicines during the 4th quarter valued at $321,000. Finally, Jennison Associates LLC acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at $31,417,000.

Insider Activity at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now owns 67,109 shares of the company’s stock, valued at $7,391,385.26. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now directly owns 157,557 shares of the company’s stock, valued at $14,143,891.89. This trade represents a 8.69 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,577 shares of company stock worth $4,768,439. 4.21% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Wells Fargo & Company reduced their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Piper Sandler upped their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $123.83.

Blueprint Medicines Stock Down 1.2 %

NASDAQ BPMC opened at $91.33 on Wednesday. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The stock has a market cap of $5.84 billion, a PE ratio of -84.56 and a beta of 0.61. The firm has a 50-day simple moving average of $99.38 and a 200 day simple moving average of $94.42. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.